DE202012013369U1 - Fertile transgene Tiere, brauchbar zum Herstellen von Antikörpern, die humane variable Regionen tragen - Google Patents

Fertile transgene Tiere, brauchbar zum Herstellen von Antikörpern, die humane variable Regionen tragen Download PDF

Info

Publication number
DE202012013369U1
DE202012013369U1 DE202012013369.1U DE202012013369U DE202012013369U1 DE 202012013369 U1 DE202012013369 U1 DE 202012013369U1 DE 202012013369 U DE202012013369 U DE 202012013369U DE 202012013369 U1 DE202012013369 U1 DE 202012013369U1
Authority
DE
Germany
Prior art keywords
mouse
human
heavy chain
antibody
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202012013369.1U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45572821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE202012013369(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/310,431 external-priority patent/US20120204278A1/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of DE202012013369U1 publication Critical patent/DE202012013369U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE202012013369.1U 2011-12-02 2012-11-30 Fertile transgene Tiere, brauchbar zum Herstellen von Antikörpern, die humane variable Regionen tragen Expired - Lifetime DE202012013369U1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13/310,431 US20120204278A1 (en) 2009-07-08 2011-12-02 Animal models and therapeutic molecules
US201113310431 2011-12-02
GBGB1122047.2A GB201122047D0 (en) 2011-12-21 2011-12-21 Transgenic animals
GB201122047 2011-12-21
US201213416684 2012-03-09
US13/416,684 US9447177B2 (en) 2009-07-08 2012-03-09 Transgenic mouse homozygous for chimeric IgH locus

Publications (1)

Publication Number Publication Date
DE202012013369U1 true DE202012013369U1 (de) 2016-08-23

Family

ID=45572821

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202012013369.1U Expired - Lifetime DE202012013369U1 (de) 2011-12-02 2012-11-30 Fertile transgene Tiere, brauchbar zum Herstellen von Antikörpern, die humane variable Regionen tragen

Country Status (11)

Country Link
US (2) US20130243759A1 (https=)
EP (4) EP2649184B1 (https=)
JP (4) JP2015502149A (https=)
CN (1) CN104160031B (https=)
AU (5) AU2012343587B2 (https=)
BR (1) BR112014013121A2 (https=)
CA (1) CA2857569A1 (https=)
DE (1) DE202012013369U1 (https=)
ES (1) ES2816899T3 (https=)
GB (1) GB201122047D0 (https=)
WO (1) WO2013079953A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
ME03551B (me) 2012-06-12 2020-07-20 Regeneron Pharma Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
EP4545567A3 (en) * 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3988649B1 (en) * 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
WO2015108102A1 (ja) 2014-01-15 2015-07-23 国立大学法人 群馬大学 Ａｔｐ可視化動物およびその用途
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
SI3161128T1 (sl) * 2014-06-26 2019-02-28 Regeneron Pharmaceuticals, Inc. Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
JP2019513415A (ja) * 2016-04-04 2019-05-30 イーティーエッチ チューリッヒ タンパク質産生及びライブラリー生成のための哺乳類細胞株
CA3079681A1 (en) * 2017-10-20 2019-04-25 Fred Hutchinson Cancer Research Center Systems and methods to produce b cells genetically modified to express selected antibodies
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
EP3785536B2 (en) * 2019-08-28 2025-09-17 Trianni, Inc. Adam6 knockin mice
JP2023529846A (ja) 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CN118325896A (zh) * 2023-01-09 2024-07-12 上海交通大学医学院 一种抗体无功能等位基因小鼠模型及其构建方法和应用
TW202600011A (zh) 2023-01-18 2026-01-01 美商基利科學股份有限公司 具有經改變重鏈基因座之嵌合基因轉殖免疫球蛋白小鼠及其製造及使用方法
WO2025055311A1 (zh) * 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129142A1 (de) 1983-06-07 1984-12-27 Elasto-Press Schmitz GmbH Mangelband für Wäschemangeln
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US5859301A (en) 1993-12-23 1999-01-12 Dsm N.V. Process for preparing alkanones and alkanols
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP1204740A1 (en) 1999-07-09 2002-05-15 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
WO2002066630A1 (en) 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6461818B1 (en) 1996-06-26 2002-10-08 Baylor College Of Medicine Method for chromosomal rearrangement by consecutive gene targeting of two recombination substrates to the deletion endpoints
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6638768B1 (en) 1989-03-20 2003-10-28 Institut Pasteur Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1399559A2 (en) 2001-06-21 2004-03-24 The Babraham Institute Mouse lambda light chain locus
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2007069666A1 (ja) 2005-12-13 2007-06-21 Kyoto University 核初期化因子
WO2008118820A2 (en) 2007-03-23 2008-10-02 Wisconsin Alumni Research Foundation Somatic cell reprogramming
WO2008124133A1 (en) 2007-04-07 2008-10-16 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
WO2008151058A2 (en) 2007-05-30 2008-12-11 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
WO2009006997A1 (en) 2007-06-15 2009-01-15 Izumi Bio, Inc. Human pluripotent stem cells and their medical use
US7501552B2 (en) 1991-08-28 2009-03-10 Medarex, Inc. Transgenic non-human animals for producing chimeric antibodies
WO2009076464A2 (en) 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
WO2010109165A2 (en) 2009-03-24 2010-09-30 Erasmus University Medical Center Rotterdam Binding molecules
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules
WO2011027180A1 (en) 2009-09-07 2011-03-10 Genome Research Limited Cells and methods for obtaining them
WO2011044050A2 (en) 2009-10-06 2011-04-14 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523899A (ja) * 2000-02-24 2003-08-12 参天製薬株式会社 製品ラベルからの汚染を防ぐための容器
DE60239420D1 (de) * 2001-12-21 2011-04-21 Thrombogenics Nv Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
ME02106B (me) * 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) * 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
SG10201605675WA (en) * 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129142A1 (de) 1983-06-07 1984-12-27 Elasto-Press Schmitz GmbH Mangelband für Wäschemangeln
US6638768B1 (en) 1989-03-20 2003-10-28 Institut Pasteur Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7501552B2 (en) 1991-08-28 2009-03-10 Medarex, Inc. Transgenic non-human animals for producing chimeric antibodies
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US5859301A (en) 1993-12-23 1999-01-12 Dsm N.V. Process for preparing alkanones and alkanols
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6461818B1 (en) 1996-06-26 2002-10-08 Baylor College Of Medicine Method for chromosomal rearrangement by consecutive gene targeting of two recombination substrates to the deletion endpoints
EP1204740A1 (en) 1999-07-09 2002-05-15 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002066630A1 (en) 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1399559A2 (en) 2001-06-21 2004-03-24 The Babraham Institute Mouse lambda light chain locus
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
WO2007069666A1 (ja) 2005-12-13 2007-06-21 Kyoto University 核初期化因子
WO2008118820A2 (en) 2007-03-23 2008-10-02 Wisconsin Alumni Research Foundation Somatic cell reprogramming
WO2008124133A1 (en) 2007-04-07 2008-10-16 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
WO2008151058A2 (en) 2007-05-30 2008-12-11 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
WO2009006997A1 (en) 2007-06-15 2009-01-15 Izumi Bio, Inc. Human pluripotent stem cells and their medical use
WO2009076464A2 (en) 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
WO2010109165A2 (en) 2009-03-24 2010-09-30 Erasmus University Medical Center Rotterdam Binding molecules
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules
WO2011027180A1 (en) 2009-09-07 2011-03-10 Genome Research Limited Cells and methods for obtaining them
WO2011044050A2 (en) 2009-10-06 2011-04-14 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
Choi I, et. al., Characterization and comparative genomic analysis of intronless Adams with testicular gene expression. Genomics., April 2004;83(4):636–46
Evans JP. Fertilin beta and other ADAMs as integrin ligands: insights into cell adhesion and fertilization. Bioessays. Juli 2001;23(7):628–39
Featherstone K, Wood AL, Bowen AJ, Corcoran AE. The mouse immunoglobulin heavy chain V-D intergenic sequence contains insulators that may regulate ordered V(D)J recombination. J Biol Chem. 26. März 2010;285(13):9327–38. E-Pub 25. Jan. 2010
Han C, et. al., Comprehensive analysis of reproductive ADAMs: relationship of ADAM4 and ADAM6 with an ADAM complex required for fertilization in mice. Biol Reprod. Mai 2009;80(5):1001–8. E-Pub., 7. Jan. 2009
Harlow, E. & Lane, D. 1998, 5. Auflage, Antibodies: A Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, NY; und Pasqualini und Arap, Proceedings of the National Academy of Sciences (2004) 101:257–259
http://bacpac.chori.org/hmale11.htm
http://bacpac.med.buffalo.edu/11framehmale.htm
http://informa.bio.caltech.edu/idx_www_tree.html
http://tools.invitrogen.com/content/sfs/manuals/bac_clones_man.pdf
http://www.ncbi.nlm.nih.gov/clone/library/genomic/16/
http://www.tree.caltech.edu/lib_status.html
Huovila AP et. al., Shedding light on ADAM metalloproteinases. Trends Biochem Sci., Juli 2005;30(7):413–22
Hybridoma, Aug. 1997; 16(4):381–9; "Rapid development of affinity matured monoclonal antibodies using RIMMS"; Kilpatrick et al.
Marcello et al, Lack of tyrosylprotein sulfotransferase-2 activity results in altered sperm-egg interactions and loss of ADAM3 and ADAM6 in epididymal sperm, J Biol Chem. 15. April 2011;286(15):13060–70. E-Pub. 21. Feb. 2011
Nature, 3. Jun. 1993; 363(6428):446–8; Naturally occurring antibodies devoid of light chains; Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R
Nikaido et al, Nature 292: 845–848 (1981)
Osoegawa et al., 2001
Osoegawa K, Mammoser AG, Wu C, Frengen E, Zeng C, Catanese JJ, de Jong PJ; Genome Res., März 2001; 11(3):483–96; "A bacterial artificial chromosome library for sequencing the complete human genome"
Osoegawa, K., Woon, P.Y., Zhao, B., Frengen, E., Tateno, M., Catanese, J.J, und de Jong, P.J. (1998); "An Improved Approach for Construction of Bacterial Artificial Chromosome Libraries"; Genomics 52, 1–8
Primakoff P, Myles DG. Penetration, adhesion, and fusion in mammalian sperm-egg interaction. Science. 21. Juni 2002;296(5576):2183–5
Proc Natl Acad Sci., 27. Mai 1997; 94(11):5709–12; "The origin and efficient derivation of embryonic stem cells in the mouse"; Brook FA & Gardner RL
Proc Natl Acad Sci; 11. Okt. 2011; "Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1"; Wang et al.
Science 24. Dezember 1982: Bd. 218 Nr. 4579 S. 1319–1321; "Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas"; Crews et al
Science, 24. Dezember 1982: Band 218 Nr. 4579 S. 1319–1321; "Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas"; Crews et al.
Talbot P, Shur BD, Myles DG. Cell adhesion and fertilization: steps in oocyte transport, sperm-zona pellucida interactions, and sperm-egg fusion. Biol Reprod. 2003 Jan;68(1):1–9

Also Published As

Publication number Publication date
JP2015502149A (ja) 2015-01-22
JP2018038428A (ja) 2018-03-15
AU2012343587A1 (en) 2014-05-15
EP4282879A2 (en) 2023-11-29
AU2012343587B2 (en) 2016-07-14
EP4282879A3 (en) 2024-03-20
HK1185100A1 (zh) 2014-02-07
US20130243759A1 (en) 2013-09-19
JP2022159413A (ja) 2022-10-17
AU2021203905A1 (en) 2021-07-08
JP2020124228A (ja) 2020-08-20
WO2013079953A1 (en) 2013-06-06
EP2989894A1 (en) 2016-03-02
ES2816899T3 (es) 2021-04-06
CN104160031A (zh) 2014-11-19
US20160353719A1 (en) 2016-12-08
AU2018217308A1 (en) 2018-09-06
AU2016101604A4 (en) 2016-10-06
EP3298889A1 (en) 2018-03-28
GB201122047D0 (en) 2012-02-01
CA2857569A1 (en) 2013-06-06
AU2016101604B4 (en) 2016-11-24
EP2649184B1 (en) 2015-10-07
CN104160031B (zh) 2017-03-08
BR112014013121A2 (pt) 2019-09-24
EP2649184A1 (en) 2013-10-16
EP2989894B9 (en) 2022-12-14
AU2016244295A1 (en) 2016-11-03
EP2989894B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
DE202012013369U1 (de) Fertile transgene Tiere, brauchbar zum Herstellen von Antikörpern, die humane variable Regionen tragen
DE69333082T2 (de) Erzielen von homozygotem durch zielgerichtete genetische ereignisse
CN103429746B (zh) Adam6小鼠
DE69120146T2 (de) Erzeugung xenogener antikörper
CN104159444B (zh) 人源化的轻链小鼠
US20140331344A1 (en) Transgenic Animals
US20200205384A1 (en) Transgenic Animals
JP2015502142A (ja) トランスジェニック非ヒトアッセイ脊椎動物、アッセイおよびキット
CN104342455A (zh) 表达具有人λ可变区和小鼠恒定区的轻链的小鼠
US10149461B2 (en) Immunocompromised ungulates
HK40103542A (en) Use of fertile transgenic animals for producing antibodies bearing human variable regions
DK2649184T3 (en) USE OF FERTILIZED TRANSGENE ANIMALS FOR THE MANUFACTURE OF ANTIBODIES CARRYING HUMAN VARIABLE REGIONS
WO2023176982A1 (ja) Ｍｈｃ遺伝子群ヒト化動物
HK1185100B (en) Use of fertile transgenic animals for producing antibodies bearing human variable regions
Frazier Animal Transgenesis and Cloning

Legal Events

Date Code Title Description
R150 Utility model maintained after payment of first maintenance fee after three years
R207 Utility model specification
R151 Utility model maintained after payment of second maintenance fee after six years
R082 Change of representative

Representative=s name: GLOBAL IP EUROPE PATENTANWALTSKANZLEI, DE

R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right